Nuclear Medicine: Page 141

Navidea lands SBIR grant for cervical cancer trial

By AuntMinnie.com staff writers

Navidea Biopharmaceuticals said it has received a grant from the U.S. National Cancer Institute to fund a clinical study of its Lymphoseek radiopharmaceutical agent in women with cervical cancer.

September 22, 2014

GE gets FDA nod for Discovery IQ PET/CT system

By AuntMinnie.com staff writers

GE Healthcare has received U.S. Food and Drug Administration 510(k) clearance for its Discovery IQ PET/CT system.

September 22, 2014

ASNC: Should nuclear technologists read SPECT MPI scans?

By Wayne Forrest

BOSTON - Nuclear medicine technologists were nearly as accurate as cardiologists in reading stress-first SPECT myocardial perfusion imaging (MPI) studies, according to research presented at the American Society of Nuclear Cardiology (ASNC) meeting. The study hints at a role for technologists in determining which patients could avoid the rest portion of the scans.

September 21, 2014

FDA grants orphan designation to Navidea's Lymphoseek

By AuntMinnie.com staff writers

The U.S. Food and Drug Administration has granted orphan drug designation to Navidea Biopharmaceuticals' Lymphoseek radiopharmaceutical agent for use in sentinel lymph node detection in patients with head and neck cancer.

September 18, 2014

Lantheus touts flurpiridaz F-18 clinical data

By AuntMinnie.com staff writers

Lantheus Medical Imaging is highlighting clinical data that show reductions in radiation exposure and improved image quality with flurpiridaz F-18 PET myocardial perfusion imaging (MPI) compared to SPECT MPI.

September 17, 2014

PET sheds light on trauma symptoms

By AuntMinnie.com staff writers

Using PET imaging, researchers at NYU Langone Medical Center have linked a receptor in the brain associated with emotions to a narrow cluster of trauma symptoms, including sadness, emotional detachment, and listlessness.

September 17, 2014

NuView inks radiopharma deal with Otsuka

By AuntMinnie.com staff writers

NuView Life Sciences has signed an exclusive deal with Otsuka Pharmaceutical to develop and commercialize VPAC1, NuView's investigative genomic-based diagnostic biomarker, for detecting breast and prostate cancer on PET scans.

September 16, 2014

ImaginAb teams with Novotectid

By AuntMinnie.com staff writers

ImaginAb has inked an exclusive technology development partnership with fellow imaging agent developer Novotectid to develop antibody-based imaging agents to image CD4+ immune T cells.

September 16, 2014

FDG-PET/CT benefits breast cancer patients younger than 40

By Wayne Forrest

While guidelines recommend FDG-PET/CT only as an optional workup for women with stage III breast cancer, the hybrid modality can help women younger than 40 who have potentially aggressive stage II breast cancer, according to a study published online September 11 in the Journal of Nuclear Medicine.

September 16, 2014

News from ASTRO 2014; ultrasound for stroke; Saudi radiation awareness

By Brian Casey

September 15, 2014

ASTRO: Imaging, radiation oncology increasingly work as one

By Eric Barnes

SAN FRANCISCO - Imaging is central to the unprecedented wave of medical specialties converging on cancer care. But it will take more than what today's radiologists are trained for to better understand cancer's mysteries, according to a keynote address by Dr. Hedvig Hricak, PhD, on Monday at the American Society for Radiation Oncology (ASTRO) meeting.

September 15, 2014

ASCO BCS research highlights benefits of mobile mammo, PET/MR

By Kate Madden Yee

Screening for breast cancer with mammography isn't perfect -- and neither are the modalities used to track women already diagnosed with the disease. At the recent American Society of Clinical Oncology (ASCO) Breast Cancer Symposium (BCS) in San Francisco, researchers discussed ways to find and track breast cancer more effectively.

September 14, 2014

Previous Page

Page 141 of 438

Next Page